title: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
abstract: OBJECTIVE
  We compare the tolerability and efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with nonneurogenic diurnal urinary incontinence and symptoms of overactive bladder.
  
  
  METHODS
  Children with a history of diurnal urinary incontinence were arbitrarily assigned to extended release oxybutynin, immediate release tolterodine or long acting tolterodine. The dose was titrated until effective (onset of complete diurnal urinary continence), maximal recommended dosage was achieved or bothersome anticholinergic side effects developed. An independent observer recorded the dose used, anticholinergic side effects and efficacy of therapy (incidence of urinary frequency, urgency, posturing and urinary incontinence).
  
  
  RESULTS
  The study included 86 girls and 46 boys. There were no statistically significant differences among the 3 treatment groups regarding the presence of peripheral or central nervous system anticholinergic side effects. Extended release oxybutynin and long acting tolterodine were significantly more effective at reducing daytime urinary incontinence than immediate release tolterodine (p <0.01 and 0 <0.05, respectively). Extended release oxybutynin was significantly more effective then long acting tolterodine for complete resolution of diurnal incontinence (p <0.05).
  
  
  CONCLUSIONS
  Extended release oxybutynin and long acting tolterodine are more effective than immediate release tolterodine in decreasing diurnal urinary incontinence. Extended release oxybutynin chloride is more effective than either immediate or long acting tolterodine for control of daytime urinary incontinence and urinary frequency.
authors.affiliation: The Center for Pediatric Urology, Pediatric Surgical Associates, 2545 Chicago Avenue South #104, Minneapolis, MN 55404, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Reinberg
authors.forename: J
authors.initials: J
authors.lastname: Crocker
authors.forename: J
authors.initials: J
authors.lastname: Wolpert
authors.forename: D
authors.initials: D
authors.lastname: Vandersteen
mesh_terms: D000293:Adolescent; D001559:Benzhydryl Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D018680:Cholinergic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D003408:Cresols / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004304:Dosage Forms; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D010665:Phenylpropanolamine; D012189:Retrospective Studies; D013644:Tartrates / Q000008:administration & dosage* / Q000009:adverse effects; D000068737:Tolterodine Tartrate; D014549:Urinary Incontinence / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003408:Cresols; D003692:Delayed-Action Preparations; D004304:Dosage Forms; D008333:Mandelic Acids; D013644:Tartrates; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin